REDONDO BEACH, CA--(Marketwired - Dec 9, 2016) -, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing the implications of reimbursement for Innovus Pharmaceuticals' (OTCQB: INNV) expanding product line.

Robust Clinical Studies

Innovus Pharmaceuticals develops over-the-counter health and wellness supplements that are supported by robust clinical studies. Using this approach, the company has developed a growing pipeline of wellness products including Vesele®, Zestra®, Sensum+®, UriVarx™, Androferti®, RecalMax™, and many others. These products have all been shown to achieve statistically significant outcomes independent of prescription pharmaceuticals.

For example, the company's Vesele® is a proprietary oral dietary supplement that maximizes nitric oxide's beneficial effects on sexual function. The firm performed a U.S. human clinical use survey study evaluating erectile dysfunction accompanying endpoints and sexual satisfaction in men using Vesele® twice daily for up to four months. The results showed a 49.5% increase in erection hardness, 44.5% increase in erection maintenance, and a 34.1% increase in the ability to satisfy their partner.

Reimbursement Benefits

The U.S. medical system relies heavily on reimbursements from health insurance and health savings plans to support sales. While reimbursements are crucial for expensive pharmaceuticals and medical devices, reimbursements for supplements offer customers modest to significant discounts and open the door to higher revenue. The problem is that many conventional doctors may be hesitant to support the use of supplements given their lack of rigorous study.

Innovus Pharmaceuticals' robust clinical studies, whether double blind or use survey studies, provide the scientific backing needed for doctors to prescribe the supplements to their patients. By using reimbursements, consumers can save up to 30% on dietary supplements, which could help boost sales over time. Expanding these reimbursements to other supplements in its portfolio could further enhance sales across the men's and women's health and wellness spectrum.

Innovus recently encouraged customers using its Vesele® product to seek reimbursement from health insurance or health savings plans. These reimbursements could help consumers save as much as 30% of the cost of the supplements by obtaining a doctor's note supporting its use. If successful in expanding these reimbursements across its product lines, the company could see significant revenue growth ahead.

Last quarter, the company reported record revenue of $1.9 million and remains on track to meet its 2016 revenue guidance of $5 million. Management also improved its balance sheet by raising $3 million from institutional investors to support ongoing product launches and growth over the coming months. In 2017, the company hopes to reach $15 million in revenues and achieve profitability on its bottom line financial results.

Follow the link to read the full article:  

Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information:
Paul Archie